Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 23.00% is 47% below its 5-year average of 43.29%, near the low end of its 5-year range (23.00%–48.84%).
As of the fiscal period ended Tuesday, June 30, 2026. 32.78% below its 12-month average of 34.22%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 23.00%.
DEBT TO ASSETS RATIO
23.00%
DEBT TO ASSETS RATIO AVG TTM
34.22%
DEBT TO ASSETS RATIO AVG 3Y
41.23%
DEBT TO ASSETS RATIO AVG 5Y
43.29%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-32.78%
CURRENT VS 3Y AVG
-44.21%
CURRENT VS 5Y AVG
-46.87%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+25459.19%
vs the sector median at left
GoodRx Holdings, Inc.
Market Cap
$1.13B
Debt to Assets Ratio
23.00%
TTM Avg
34.22%
3Y Avg
41.23%
5Y Avg
43.29%
Market Cap
$1.13B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.14B
Debt to Assets Ratio
0.39%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.11B
Debt to Assets Ratio
0.44%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.11B
Debt to Assets Ratio
0.64%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10B
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.10B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GoodRx Holdings, Inc. (GDRX) | $1.13B | 23.00% | 34.22% | 41.23% | 43.29% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 0.72% | N/A | N/A | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | 0.04% | N/A | N/A | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 0.39% | N/A | N/A | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.14B | 0.12% | N/A | N/A | N/A |
| Replimune Group, Inc. (REPL)vs › | $1.11B | 0.44% | N/A | N/A | N/A |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | 0.64% | N/A | N/A | N/A |
| STAAR Surgical Company (STAA)vs › | $1.10B | 0.08% | N/A | N/A | N/A |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.10B | 0.02% | N/A | N/A | N/A |
| OPKO Health, Inc. (OPK)vs › | $1.09B | 0.21% | N/A | N/A | N/A |
Debt/Assets
23.0%
Debt/Equity
0.83
Current Ratio
1.38
Interest Coverage
2.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 23.00% |
| 2026-03-31 | 26.78% |
| 2025-12-31 | 38.66% |
| 2025-09-30 | 41.13% |
| 2025-06-30 | 41.52% |
| 2025-03-31 | 41.78% |
| 2024-12-31 | 39.15% |
| 2024-09-30 | 40.19% |
| 2024-06-30 | 47.95% |
| 2024-03-31 | 48.84% |
| 2023-12-31 | 44.76% |
| 2023-09-30 | 41.66% |
| 2023-06-30 | 42.22% |
| 2023-03-31 | 44.43% |
| 2022-12-31 | 44.68% |
| 2022-09-30 | 44.57% |
| 2022-06-30 | 44.00% |
| 2022-03-31 | 45.51% |
| 2021-12-31 | 43.69% |
| 2021-09-30 | 43.48% |
| 2021-06-30 | 44.37% |
| 2021-03-31 | 46.70% |
| 2020-12-31 | 47.95% |
| 2020-09-30 | 47.41% |
| 2020-06-30 | 146.54% |
| 2019-12-31 | 183.81% |
